Literature DB >> 7116160

Distribution of effects of haloperidol on energy metabolism in the rat brain.

J McCulloch, H E Savaki, L Sokoloff.   

Abstract

The effects of the putative dopaminergic antagonist, haloperidol (0.01-10 mg/kg, i.v.), on cerebral glucose utilization in 43 anatomically discrete regions of the rat brain have been examined by the quantitative autoradiographic 2-deoxyglucose technique. Dose-dependent reductions in glucose utilization were observed in 10 regions of the CNS (e.g. hippocampus, ventral thalamus and almost the entire neocortex, with the notable exception of anterior cingulate cortex). Two regions of the CNS (nucleus accumbens and pars compacta of the substantia nigra) displayed dose-related increases in glucose utilization following haloperidol administration. In addition to these specific alterations, the largest doses of haloperidol produced widespread, moderate (about 25%) reductions in glucose utilization throughout the CNS. The prior administration of haloperidol (0.1 mg/kg) prevented the effects on glucose utilization of the administration of apomorphine (1.5 mg/kg) in all regions of the CNS examined. The distribution of alterations in glucose utilization following haloperidol administration are considered in relation to the overall functional consequences of dopaminergic receptor blockade.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116160     DOI: 10.1016/0006-8993(82)91122-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs.

Authors:  Bruce M Cohen; Sara Cherkerzian; Jianyi Ma; Nancy Ye; Carrie Wager; Nicholas Lange
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

2.  Effects of the 5-HT1A partial agonists gepirone, ipsapirone and buspirone on local cerebral glucose utilization in the conscious rat.

Authors:  P M Grasby; T Sharp; T Allen; P A Kelly; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration.

Authors:  N D Volkow; J D Brodie; A P Wolf; B Angrist; J Russell; R Cancro
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

4.  Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography.

Authors:  G Wik; F A Wiesel; I Sjögren; G Blomqvist; T Greitz; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Savoxepine fails to selectively influence glucose metabolism in the rat limbic system.

Authors:  N G Cascella; F I Tarazi; O Shirakawa; C A Tamminga
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

6.  PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function.

Authors:  K J Black; M H Gado; J S Perlmutter
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  Antagonism of cocaine's stimulant effects on local cerebral glucose utilization by the preferential autoreceptor antagonist (+)-AJ 76.

Authors:  B L Casey; C A Ray; M F Piercey
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.